Get the Stockscreener App
4.78
0.84%
0.04
After Hours:
4.78
Eledon Pharmaceuticals Inc stock is traded at $4.78, with a volume of 247.05K.
It is up +0.84% in the last 24 hours and up +15.46% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$4.74
Open:
$4.74
24h Volume:
247.05K
Relative Volume:
0.40
Market Cap:
$285.55M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-2.6704
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+12.47%
1M Performance:
+15.46%
6M Performance:
+73.19%
1Y Performance:
+164.09%
1-Day Range:
$4.60
$4.86
1-Week Range:
$4.17
$4.86
52-Week Range:
$1.5199
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
4.78 | 285.55M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Eledon CEO to Reveal Latest Biotech Developments at Major Guggenheim Conference - StockTitan
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business - Seeking Alpha
Guggenheim Initiates Eledon Pharmaceuticals at Buy With $9 Price Target -January 28, 2025 at 07:34 am EST - Marketscreener.com
Eledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Inspire Investing LLC Invests $802,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Midday Stock Roundup: FivePoint Holdings Jumps 36% - Orange County Business Journal
Cantor Fitzgerald Comments on ELDN FY2025 Earnings - Defense World
Kidney Transplant Rejection Market Expected to Experience - openPR
Cantor Fitzgerald Weighs in on ELDN FY2025 Earnings - MarketBeat
Analyst Forecast For Eledon Pharmaceuticals Inc (NASDAQ: ELDN) - Stocks Register
Eledon Pharmaceuticals highlights recent business milestones, 2025 outlook - MSN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook - GlobeNewswire
Eledon's Tegoprubart Achieves Major Breakthrough in Kidney Transplant Trials, Secures $135M Funding - StockTitan
Geode Capital Management LLC Buys 33,569 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.9%Should You Sell? - MarketBeat
Eledon Pharmaceuticals adjusts CEO bonus structure - Investing.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Has Negative Outlook for ELDN Q4 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for ELDN Earnings - MarketBeat
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress - Investing.com Australia
Eledon Pharmaceuticals retains shares target, Buy rating on clinical trial progress By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals (NASDAQ:ELDN) Given Buy Rating at HC Wainwright - MarketBeat
FY2024 EPS Estimates for ELDN Boosted by Cantor Fitzgerald - MarketBeat
Lifesci Capital Issues Optimistic Outlook for ELDN Earnings - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance
Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St
Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian
Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):